In this week’s video, Dr. Brian Durie discusses the value of ASCT even with the use of newer drug regimens.

We still value high-dose melphalan with ASCT in 2017.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
Best Therapies for Patients Opting for Transplant - Boca Raton PFS 2017
Next Post
New Studies Examine the Use of Liquid Biopsies and the Possible Causes of Myeloma

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.